Navigation Links
Esperion Therapeutics Initiates Phase 2 Clinical Study for ETC-1002
Date:1/6/2011

PLYMOUTH, Mich., Jan. 6, 2011 /PRNewswire/ -- Esperion Therapeutics, a privately held biotechnology company working to discover, develop and commercialize treatments for cardiovascular and metabolic diseases, today announced that it has initiated a Phase 2 clinical study for ETC-1002, the company's lead product candidate. ETC-1002 is a novel small molecule compound that has demonstrated preclinical and clinical activity as a metabolic regulator of imbalances in lipid and carbohydrate metabolism. The compound acts to inhibit fatty acid and cholesterol synthesis and enhance fatty acid oxidation. ETC-1002 has the potential to regulate LDL-C, HDL-C, triglycerides, glucose/insulin and other cardio-metabolic risk factors.

The 12-week, multi-site, randomized, double-blind, placebo controlled study will enroll 176 patients with hypercholesterolemia, with or without high triglycerides, to assess the role of ETC-1002 in lipid regulation (LDL-C and triglycerides). This Phase 2 trial builds on positive data from the Phase 1 program in which ETC-1002 demonstrated a statistically significant lowering of LDL-C in mildly dyslipidemic subjects and a favorable safety profile in both single and multiple-dose studies in more than 70 patients. A second Phase 2 clinical study is planned in 2011 to validate other attributes observed in preclinical studies with ETC-1002 which further support its pharmacological effects as a metabolic regulator.

"Cardio-metabolic diseases remain the leading cause of morbidity and mortality among men and women in industrialized countries worldwide," said Roger Newton, PhD, President and CEO of Esperion. "Our preclinical research has shown ETC-1002 regulates lipids, atherosclerosis, inflammation and glucose/insulin. These data, along with the accumulating clinical evidence, suggest that ETC-1002 may be an effective therapy to regulate metabolic imbalances in lipid and carbohydrate metabolism and could play a significant role in the treatment
'/>"/>

SOURCE Esperion Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. TransGenRx Protein Therapeutics Technology to Support Research Related to Protein-Based HDL Therapies at Esperion Therapeutics
2. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
3. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
4. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
5. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
6. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
7. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
8. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
9. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
10. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
11. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... , Nov. 21, 2014  World Hemp Oil, ... low THC, announces they are now offering legal, organic ... Charlotte,s Web type strains grown in medical marijuana states. ... neurological disorders, such as Parkinson,s, MS, and spinal cord ... laws to pass, because imported CBD Oil Is legal ...
(Date:11/21/2014)... Nov. 21, 2014  Abaxis, Inc. (NasdaqGS: ... and consumables for the medical, research, and veterinary markets ... and research markets in the United States ... purchase agreement to acquire 100% of QCR & Trio ... based distribution organization. The transaction closed on November 17, ...
(Date:11/21/2014)... MONTREAL , 21. November 2014 ... hat heute bekannt gegeben, dass ... – EMA) die Kennzeichnung als Orphan-Medizinprodukt ... Produktkandidat des Unternehmens zur Behandlung von ... eine seltene, stark beeinträchtigende genetische Krankheit, ...
Breaking Medicine Technology:New CBD Oil From Industrial Hemp is Comparable to Charlotte's Web, Legal In All 50 States 2New CBD Oil From Industrial Hemp is Comparable to Charlotte's Web, Legal In All 50 States 3Abaxis Acquires UK-based Distribution Organization 2Abaxis Acquires UK-based Distribution Organization 3Abaxis Acquires UK-based Distribution Organization 4Clementia Pharmaceuticals erhält EMA-Kennzeichnung als Orphan-Medizin für Palovarotene zur Behandlung von Fibrodysplasia ossificans progressiva 2Clementia Pharmaceuticals erhält EMA-Kennzeichnung als Orphan-Medizin für Palovarotene zur Behandlung von Fibrodysplasia ossificans progressiva 3
... June 21, 2011 Robbins & Myers, Inc. (NYSE: ... of Directors has approved its regular quarterly cash dividend ... on August 5, 2011 to shareholders of record as ... Inc. is a leading supplier of engineered equipment and ...
... 2011 Reportlinker.com announces that a new market ... The Outlook for Medical Devices in ... Detailed analysis of four ... global medical device market and which present immense ...
Cached Medicine Technology:Reportlinker Adds The Outlook for Medical Devices in North East Asia 2Reportlinker Adds The Outlook for Medical Devices in North East Asia 3Reportlinker Adds The Outlook for Medical Devices in North East Asia 4
(Date:11/24/2014)... Abington, PA (PRWEB) November 24, 2014 ... Nataliya Ternopolska, MD has joined The Neurology ... Abington Health’s Multiple Sclerosis Center. , A graduate ... residency in Neurology at Albert Einstein Medical Center in ... the Judith Jaffe Multiple Sclerosis Center at Weill Cornell ...
(Date:11/24/2014)... New York (PRWEB) November 24, 2014 ... contacted by the Family and Children's Association ... such as soap, shampoo, mouthwash and other such items.The ... citizens who are home bound, living in nursing homes, ... intended to greatly enhance the well being of seniors ...
(Date:11/24/2014)... 24, 2014 ReAdmission Solutions, LLC ... management services to health plans, hospitals, and accountable ... Management software suite. ReAdmission Solutions will use ... program to reduce patients' avoidable readmissions to hospitals. ... Care Management, Utilization Management, and Appeals & Grievances. ...
(Date:11/23/2014)... iFitDress.com, a well-known wedding dress manufacturer, has unveiled ... They are now offered at deeply discounted prices, up ... now to Dec. 15. The main purpose of the promotion ... high quality items are ideal options for ladies who are ... money. All its new mint cocktail dresses are very beautiful; ...
(Date:11/23/2014)... 23, 2014 Nearly 260 testosterone ... strokes, deep vein thrombosis and other serious cardiovascular ... multidistrict litigation (MDL) underway in the Northern District ... Court documents updated on November 17th by the ... the filing of 259 lawsuits against the makers ...
Breaking Medicine News(10 mins):Health News:Nataliya Ternopolska Named Associate Medical Director of Abington Health’s Multiple Sclerosis Center 2Health News:The Holiday Inn Westbury - Long Island gives back to the local Long Island community, and also goes beyond borders to assist those in need during the 2014 Holiday Season 2Health News:The Holiday Inn Westbury - Long Island gives back to the local Long Island community, and also goes beyond borders to assist those in need during the 2014 Holiday Season 3Health News:ReAdmission Solutions, LLC Selects Essette 2Health News:Trendy Long Black Evening Gowns Now Provided By iFitDress.com 2Health News:Testosterone Lawsuits Approach 260 in Illinois Federal Court Litigation, Bernstein Liebhard LLP Reports 2Health News:Testosterone Lawsuits Approach 260 in Illinois Federal Court Litigation, Bernstein Liebhard LLP Reports 3
... life is a myth, argues a senior doctor in a letter ... Kelly Taylor, a terminally ill woman who went to court earlier ... morphine, even though it will hasten her death. ... the principle of double effect is a puzzling choice, writes Claud ...
... health and reduce days off work and school, according to ... state of housing has a real impact on health; cold ... likely to be damp - leading to respiratory problems. Despite ... little is known about the specific health effects of the ...
... women are at a higher risk of perinatal mortality (death ... black or white women// , concludes a study published online ... defines post-term pregnancy as beyond 41 completed weeks from the ... associated with increased perinatal mortality, and induction of labour at ...
... Administration (FDA) and the Centers for Disease Control and Prevention ... that has not been// pasteurized, known as raw milk. ... – including Salmonella, E. coli O157:H7, Listeria, Campylobacter and Brucella ... ,Consuming raw milk may be harmful to health. ...
... and family difficulties account for about half of all ... family therapy work chiefly with couples.// The therapist helps ... and unstated assumptions that perpetuate conflict, explains the March ... ,Couples therapists make little use of psychiatric ...
... at the University of Illinois have found that a molecular ... bone cancer in humans is also critical to the pathology// ... lead to advances in the palliative care of companion animals ... U. of I. pathobiology professor Anne Barger, examined the homeostatic ...
Cached Medicine News:Health News:Insulating Houses Improves Health and Wellbeing 2Health News:FDA and CDC Remind Consumers of the Dangers of Drinking Raw Milk 2Health News:Insights into Osteosarcoma in Cats and Dogs may Improve Palliative Care 2
... single-use is designed to saturate dry eyes, ... very dry eyes. For maximum hydration and ... dosing--splitting the entire contents of one container, ... after opening at least 4 times a ...
POLYSORB™ sutures are composed of LACTOMER™ glycolide/lactide copolymer which is a synthetic polyester composed of glycolide and lactide (derived from glycolic and lactic acids)....
Surgitie&trade Single Use Ligating Loops with Delivery System...
Surgitie&trade Single Use Ligating Loops without Delivery System with POLYSORB™....
Medicine Products: